Clinical trials: Endocrine Disorder
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Ixabepilone in Treating Patients With Ovarian Epithelial or Primary Peritoneal Cancer That Has Not Responded to Previous Chemotherapy
Phase II trial to study the effectiveness of ixabepilone in treating patients who have recurrent or persistent ovarian epithelial or primary peritoneal cancer that has not responded to previous chemotherapy.
- Trial name
- NCT00025155
- Testing
- ixabepilone
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Foot Ulcers
DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes
A randomized versus placebo trial designed to evaluate the clinical and humoral effects of 4 months of vildagliptin on healing of chronic ulcers in type 2 diabetes.
- Trial name
- NCT01472432
- Testing
- vildagliptin
- Where
- Italy
- Volunteers
- 106 people
- Sponsor
- University of Campania Luigi Vanvitelli
Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
This is an open-label study evaluating the safety and efficacy of CP101 treatment in 1) Subjects in CDI-001 who had a CDI recurrence within 8 weeks of receiving CP101 or placebo; OR 2) adults with recurrent CDI who are eligible…
- Conditions
- Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI
- Trial name
- PRISM-EXT (NCT03497806)
- Testing
- CP101
- Where
- 57 sites in United States, Canada
- Volunteers
- 132 people
- Sponsor
- Finch Research and Development LLC.
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Pancreatic Cancer
BPM31510 Administered Intravenously With Gemcitabine in Advanced Pancreatic Cancer Patients
This is a Phase 2 multicenter, open-label, non-randomized study to examine the safety and effectiveness of BPM31510 administered over 144-hours (two 72-hour 110mg/Kg doses) continuous intravenous (IV) infusion in combination with…
- Trial name
- NCT02650804
- Testing
- BPM31510 Nanosuspension Injection, Gemcitabine
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 45 people
- Sponsor
- BPGbio
Diabetes Mellitus, Type 2
A Non Interventional Study to Monitor the Safety and Effectiveness of Trajenta (Linagliptin, 5 mg, q.d) in Korean Patients With Type 2 Diabetes Mellitus
The aim of this study is to monitor safety and efficacy of treatment with linagliptin in Korean patients with type 2 diabetes mellitus in routine clinical settings.
- Trial name
- NCT01707147
- Testing
- Trajenta tablet
- Where
- South Korea
- Volunteers
- 3,219 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer
Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants With HR+, HER2-, Advanced Breast Cancer While on Treatment With Alpelisib and Fulvestrant
This study was designed to assess the safety and efficacy of the combination of dapagliflozin plus metformin extended release (XR) compared with metformin XR during treatment with alpelisib plus fulvestrant in participants with…
- Trial name
- EPIK-B4 (NCT04899349)
- Testing
- Alpelisib, Fulvestrant, Metformin XR
- Where
- 2 sites in United States, Malaysia
- Volunteers
- 2 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to basal insulin with or without sulfonylurea, over a period of 24 weeks of treatment.
- Trial name
- GETGOAL-L-ASIA (NCT00866658)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Sulfonylurea
- Where
- 4 sites in Japan, Philippines and 2 more
- Volunteers
- 311 people
- Sponsor
- Sanofi
Hypogonadism, Male
Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).
Multicenter, open-label, one treatment study evaluating the efficacy of LPCN 1021 in adult hypogonadal male subjects.
- Trial name
- DV (NCT03242590)
- Testing
- LPCN 1021
- Volunteers
- 95 people
- Sponsor
- Lipocine Inc.
Diabetes Mellitus, Type 1
GPR119 Agonist for Hypoglycemia in Type 1 Diabetes
The purpose of this study is to test if a specific research medication could increase the response to low blood glucose in people with type 1 diabetes.
- Trial name
- PHROG (NCT04432090)
- Testing
- Study Medication (MBX-2982), No medication for this group
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Type 2 Diabetes
My Diabetes, My Community
Older adults with diabetes are a highly vulnerable population that suffers the highest rates of cardiovascular and microvascular complications as well as adverse drug events such as hypoglycemia.
- Trial name
- NCT04970810
- Testing
- My Diabetes Goal, My Diabetes Goal + CommunityRx
- Where
- United States
- Volunteers
- 512 people
- Sponsor
- University of Chicago
Type 2 Diabetes Mellitus
MK0431 (Sitagliptin) Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus (0431-055)(COMPLETED)
The clinical study determines the safety and efficacy of MK0431 in patients with type 2 diabetes mellitus who have inadequate glycemic control on pioglitazone as monotherapy.
- Trial name
- NCT00372060
- Testing
- sitagliptin phosphate, Comparator: sitagliptin phosphate (MK0431), Comparator: pioglitazone
- Volunteers
- 134 people
- Sponsor
- Merck Sharp & Dohme LLC
Cervical Carcinoma, Endometrioid Adenocarcinoma
Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers
This phase I trial studies the side effects and best dose of adavosertib when given together with external beam radiation therapy and cisplatin in treating patients with cervical, vaginal, or uterine cancer.
- Conditions
- Cervical Carcinoma, Endometrioid Adenocarcinoma, Malignant Female Reproductive System Neoplasm, Recurrent Cervical Carcinoma
- Trial name
- NCT03345784
- Testing
- Adavosertib, Cisplatin, External Beam Radiation Therapy
- Where
- 8 sites in United States, Canada
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Type 1 Diabetes
Study to Compare Efficacy of the MiniMed Paradigm REAL-Time System Vs. MDI in Subjects Naive to Insulin Pump Therapy
Primary Outcomes: Average decrease in A1c from baseline to end of Study Phase (52 weeks) for subjects in the "722 Group" is greater than that for subjects in the "Control (MDI) Group".
- Trial name
- STAR3 (NCT00417989)
- Testing
- MiniMed Paradigm REAL-Time System
- Where
- 30 sites in United States, Canada
- Volunteers
- 485 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus on Background of Metformin
Primary Objective: To demonstrate the superiority of Sotagliflozin versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control with metformin.
- Trial name
- NCT02926950
- Testing
- Sotagliflozin (SAR439954), Metformin
- Where
- 93 sites in United States, Canada and 2 more
- Volunteers
- 518 people
- Sponsor
- Lexicon Pharmaceuticals
Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
This randomized phase III trial studies paclitaxel and carboplatin see how well they work compared with paclitaxel and ifosfamide in treating patients with fallopian tube, or peritoneal cavity cancer that is newly diagnosed…
- Conditions
- Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT00954174
- Testing
- Carboplatin, Ifosfamide, Paclitaxel
- Where
- 538 sites in United States, South Korea
- Volunteers
- 637 people
- Sponsor
- GOG Foundation
Hypogonadism, Male
Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men
The purpose of this six-month treatment study is to assess feasibility of a lower starting dose of SOV2012-F1 (daily dose of 400 mg [200 mg with breakfast meal and 200mg with dinner meal]) to titrate individual doses to further…
- Trial name
- NCT04467697
- Testing
- SOV2012-F1
- Where
- 19 sites in United States
- Volunteers
- 155 people
- Sponsor
- Marius Pharmaceuticals
Diabetes Mellitus, Peripheral Neuropathy
Botulinum Toxin Effects on Plantar Ulcer Recurrence
The purpose of this grant is to collect pilot data to assess the amount of botulinum toxin that needs to be injected into the calf muscles of subjects with diabetes mellitus, peripheral neuropathy, and a plantar ulcer to decrease…
- Conditions
- Diabetes Mellitus, Peripheral Neuropathy, Plantar Ulcers
- Trial name
- NCT00845897
- Testing
- Botulinum Toxin, Saline
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Washington University School of Medicine
Diabetes Mellitus, Type 1
A Study to Compare LY2963016 to Lantus After a Single Dose to Participants With Type 1 Diabetes Mellitus
The study involves a single injection of LY2963016 and a single injection of Lantus, on 2 separate occasions in participants with type I diabetes.
- Trial name
- NCT01600950
- Testing
- LY2963016, Lantus
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine
This study will examine the safety and efficacy of albiglutide in combination with insulin glargine as compared with the combination of insulin glargine and preprandial lispro insulin in subjects with type 2 diabetes.
- Trial name
- NCT00976391
- Testing
- albiglutide + insulin glargine, insulin glargine + preprandial lispro insulin
- Where
- 209 sites in United States, Brazil and 12 more
- Volunteers
- 586 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.